Prospecto:Information for the User
Risperidona Teva 25 mg powder and solvent for prolonged-release injectable suspension EFG
Risperidona Teva 37.5 mg powder and solvent for prolonged-release injectable suspension EFG
Risperidona Teva 50 mg powder and solvent for prolonged-release injectable suspension EFG
Read this prospectus carefully before starting to use this medication,because it contains important information for you.
1.What is Risperidona Tevaandwhatisitusedfor
2.What you need to knowbeforestartingtouseRisperidona Teva
3.How to use Risperidona Teva
4.Possible adverse effects
5.Storage of Risperidona Teva
6.Contents of the package and additional information
Risperidona belongs to a group of medicines called “antipsychotics”.
Risperidona is used in the maintenance treatment of schizophrenia, which is characterized by seeing, hearing or feeling things that are not present, believing in something that is not true or unusually feeling distrust or confusion.
Risperidona is intended for patients who are currently being treated with oral antipsychotics (e.g., tablets, capsules).
Risperidona may help reduce the symptoms of your illness and prevent them from returning.
Do not use Risperidona Teva
Warnings and precautions
Consult your doctor or pharmacist before starting to use Risperidona Teva if:
If you are unsure whether the information above affects you, talk to your doctor or pharmacist before using risperidone or Risperidona Teva powder and solvent for prolonged-release suspension for injection EFG.
Because in very rare cases, a dangerously low number of a type of white blood cell necessary to fight infections in the blood has been observed in patients treated with risperidone, your doctor may check your white blood cell count.
Rarely, allergic reactions occur after receiving injections of risperidone, even if you have previously tolerated oral risperidone. Seek medical attention immediately if you experience hives, swelling of the throat, itching or breathing difficulties as these may be symptoms of a severe allergic reaction.
Risperidone may cause you to gain weight. A significant weight gain may affect your health unfavourably. Your doctor will regularly monitor your weight.
Because diabetes mellitus or worsening of pre-existing diabetes mellitus has been seen in patients taking risperidone, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be monitored regularly.
Risperidone frequently increases the levels of a hormone called “prolactin”. This may cause adverse effects such as menstrual disorders or fertility problems in women, or breast swelling in men (see Possible adverse effects). If these adverse effects appear, it is recommended that blood prolactin levels be evaluated.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the coloured part of the eye) may become flaccid during surgery and this may cause eye damage. If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Patients with advanced age and dementia
Risperidone is not used in people with advanced age and dementia.
If you or your caregiver notice a sudden change in your mental state or the sudden appearance of weakness or numbness of the face, arms or legs, especially on one side, or confused speech, even for a short time, seek medical treatment immediately. This may be a sign of a stroke.
People with kidney or liver problems
Although oral risperidone has been studied, Risperidone Teva powder and solvent for prolonged-release suspension for injection EFG has not been studied in patients with kidney or liver problems. Risperidone should be administered with caution in this group of patients.
Use of Risperidona Teva with other medicines
Inform your doctor or pharmacist if you are using or have recently used or may need to use any other medicine.
It is especially important to talk to your doctor or pharmacist if you take any of the following
The following medicines may reduce the effect of risperidone
If you start or stop taking these medicines, you may need a different dose of risperidone.
The following medicines may increase the effect of risperidone
If you start or stop taking these medicines, you may need a different dose of risperidone.
If you are unsure whether the information above affects you, talk to your doctor or pharmacist before using risperidone.
Use of Risperidona Teva with food, drinks and alcohol
You should avoid consuming alcohol while using risperidone.
Pregnancy, breastfeeding and fertility
Driving and operating machinery
Dizziness, tiredness and vision problems have been observed during treatment with risperidone. Do not drive or use tools or machinery without consulting your doctor first.
Risperidona Teva contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per dose; that is, it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Risperidona Teva is administered via intramuscular injection in the arm or buttock every two weeks by a healthcare professional. The injections should be alternated between the left and right sides and should not be administered intravenously.
The recommended dose is as follows:
Adults
Initial dose
If your daily dose of oral risperidone (e.g., tablets) was 4 milligrams or less during the previous two weeks, your initial dose should be 25 milligrams of Risperidona Tevapowder and solventfor long-acting injectable suspension EFG.
If your daily dose of oral risperidone (e.g., tablets) was more than 4 milligrams during the previous two weeks, you may be given a dose of 37.5 milligrams of Risperidona Tevapowder and solventfor long-acting injectable suspension EFGas the initial dose.
If you are currently being treated with another oral antipsychotic that is not risperidone, your initial dose of Risperidona Tevapowder and solventfor long-acting injectable suspension EFGwill depend on your current treatment. Your doctor will choose Risperidona Teva 25 mg or 37.5 mg.
Your doctor will decide if this dose of risperidone is suitable for you.
Maintenance dose
If you use more Risperidona Teva than you should
If you interrupt treatment with Risperidona Teva
You will lose the effects of this medication. Do not stop using this medication unless your doctor has told you to, as you may experience symptoms again. Make sure to receive your injections every two weeks. If you cannot attend your appointments, contact your doctor immediately to schedule another appointment when you can.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Use in children and adolescents
Children and adolescents under 18 years old should not receive risperidone.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if you experience any of the following rare side effects (which may affect up to 1 in 100 patients):
Inform your doctor immediately if you experience any of the following rare side effects (which may affect up to 1 in 1,000 patients):
You may also experience the following side effects:
Very common side effects(which may affect more than 1 in 10 people)
Common side effects(which may affect up to 1 in 10 people)
Rare side effects(which may affect up to 1 in 100 people)
Rare side effects(which may affect up to 1 in 1,000 people)
Very rare side effects(which may affect up to 1 in 10,000 people)
The following side effect has appeared with the use of another medication called paliperidone, which is very similar to risperidone, so it is also expected to appear with risperidone: Fast heart rate when standing up.
Unknown frequency:(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Store in refrigerator (between 2°C and 8°C). If refrigeration is not available, the packaging can be stored below 25°C for a maximum of 7 days before administration.
Store in the original packaging to protect it from light.
After reconstitution:
Physical and chemical stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, storage conditions and times before use are the responsibility of the user and should normally not exceed 6 hours at 25°C, unless reconstitution was made in controlled and validated aseptic conditions.
Medicines should not be disposed of through drains or trash. Dispose of packaging and unused medications at the SIGRE point of the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and unused medications. This will help protect the environment.
Composition of Risperidona Teva
Polvo para suspensión para inyección:
Poli-(D, L-láctido-co-glicólido)
Disolvente (solución):
Polisorbato 20, carmelosa sódica, fosfato hidrogenado disódico dihidratado, ácido cítrico, cloruro sódico, hidróxido sódico, agua para inyectables.
Aspecto del producto y contenido del envase
Risperidona 25 mg:
Each package contains the following components grouped in a plastic tray:
Risperidona 37.5 mg:
Each package contains the following components grouped in a plastic tray:
Risperidona 50 mg:
Each package contains the following components grouped in a plastic tray:
Risperidona Teva is available in packages containing 1, 2, or 5 doses.
Only some package sizes may be marketed.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Teva Pharma, S.L.U.
C/Anabel Segura, 11 Edificio Albatros B, 1ª planta
28108 Alcobendas (Madrid)
Spain
Responsible Manufacturer
PLIVA Hrvatska d.o.o. (PLIVA Croatia Ltd.)
Prilaz baruna Filipovica 25
10000 Zagreb
Croatia
or
Pharmathen International S.A
Industrial Park Sapes,
Rodopi Prefecture, Block No 5,
Rodopi 69300,
Greece
or
Pharmathen S.A
Dervenakion 6,
Pallini Attiki,
15351,Greece
Last revision date of thisleaflet:March 2022
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
----------------------------------------------------------------------------------------------------------------------------------
This information is intended solely for healthcare professionals:
Important information
Risperidona Teva requires careful attention at each step of the “Instructions for Use” to help ensure a successful administration.
Use of the provided components
The components of the package are specifically designed for use with Risperidona Teva.
Risperidona Teva must be reconstituted only with the solvent provided in the package.
Do notsubstitute any of the components of this package.
Do notstore the suspension after reconstitution.
Administer the dose as soon as possible after reconstitution, to avoid sedimentation.
Adequate dose
The entire contents of the vial must be administered to ensure that the adequate dose of Risperidona Teva is administered.
Do not re-use
Medical devices require materials with specific characteristics to function properly. These characteristics have been verified for single use. Any attempt to reprocess the device for subsequent reuse may affect the integrity of the device or lead to deterioration of its function.
Components of the package
Step 1 | Assemble the components | ||
Remove the dose package | Connect the vial adapter to the vial | ||
Wait 30 minutes Remove the dose package from the refrigerator and let it reach room temperature for at least30 minutesbefore reconstitution. Do not heat it in any other way. | Remove the vial cap Remove the colored cap from the vial. Clean the top of the gray stopper with analcohol swab. Let it air dry. Do notremove the gray rubber stopper. | Prepare the vial adapter Open the blister pack and remove the vial adapter, holding it between the white capsule and the edge. Do nottouch the tip of the needle or the luer connection point at any time. This may lead to contamination. | Attach the vial adapter to the vial Place the vial on a hard surface and hold it by the base. Center the vial adapter over the gray rubber stopper. Press the vial adapter straight down until it securely fits into the vial, confirmed when you hear “click”. Do notplace the vial adapter at an angle, as it may lose solvent during transfer to the vial. |
Attach the pre-loaded syringe to the vial adapter | |||
Clean the connection point Hold the vial vertically to prevent losses. Clean the luer connection point (blue circle) of the vial adapter with an alcohol swab and let it dry before attaching the syringe. Do notshake. Do nottouch the luer connection point of the vial adapter. This may lead to contamination. | Use the correct gripping area Hold by the white ring of the syringe tip. Do nothold the syringe by the glass during assembly. | Remove the capsule Hold the white ring and break the white capsule. Do notrotate or cut the white capsule. Do nottouch the syringe tip. This may lead to contamination. The broken capsule can be discarded. | Attach the syringe to the vial adapter Hold the vial adapter by the edge to keep it fixed. Hold the syringe by the white ring and then insert and press the syringe tip into the blue circle of the vial adapter and turn clockwise to secure the syringe to the vial adapter (avoid pressing too hard). Do nothold the syringe by the glass cylinder. This may cause the white ring to loosen or come off. |
Step 2 | Reconstitute the microspheres | ||
Inject solvent Inject the entire amount of solvent from the syringe into the vial. | Suspend the microspheres in the solvent Continue pressing down on the plunger with your finger,shakeenergetically, as shown,for at least 10 seconds. Check the suspension. When properly mixed, the suspension will have a uniform, dense, and milky appearance. The microspheres will be visible in the liquid. Immediately proceed to the next step to avoid sedimentation. | Transfer the suspension to the syringe Invert the vial completely. Pull the plunger rod slowly down to transfer the entire contents of the vial to the syringe. | Remove the vial adapter Hold the syringe by the white ring and disengage it from the vial adapter. Discard the vial and vial adapter properly. |
Step 3 | Place the needle | |
Choose the correct needle Choose the needle according to the injection site (gluteal or deltoid). | Place the needle Open the blister pack by the partially separated area and use it to pick up the base of the needle, as shown. Holding the white ring of the syringe,attach the syringe to the needle of the luer with a firmrotational movement in a clockwise directionuntil it is securely attached. Do nottouch the opening of the needle of the luer. This may lead to contamination. | Resuspend the microspheres Remove the blister pack completely. Just before injection, shake the syringe again vigorously, in case sedimentation has occurred. |
Step 4 | Inject the dose | |||
Remove the transparent needle protector Moving the needle safety device towards the syringe, as shown. Then, hold the white ring of the syringe and carefully remove the transparent needle protector. Do nottwist the transparent needle protector, as the luer connection may be lost. | Remove air bubbles Holding the syringe upwards and gently tapping to make the air bubbles reach the top. Slowly and carefully press the plunger rod to remove the air. | Inject Inject the entire contents of the syringe intramuscularly (IM) into the gluteal or deltoid muscle of the patient. The gluteal injection should be made in the upper outer quadrant of the gluteus. Do not administer intravenously. | Protect the needle in the safety device Usingone hand, place the needle safety device at a 45-degree angle on a flat, hard surface. Press down firmly and quickly until the needle is completely inside the safety device. To avoid a needlestick injury: Do notuse two hands. Do notdeliberately disengage or manipulate the needle safety device. Do notattempt to straighten the needle or attach the safety device if the needle is bent or damaged. | Properly dispose of the needles Check that the needle safety device is securely attached. Dispose of it in a used needle container. Also discard the needle provided in the package and the unused dose. |
O preço médio do Risperidona teva 50 mg polvo y disolvente para suspension inyectable de liberacion prolongada efg em julho de 2025 é de cerca de 138.28 EUR. Os valores podem variar consoante a região, a farmácia e a necessidade de receita. Confirme sempre com uma farmácia local ou fonte online para obter informações atualizadas.
Tem perguntas sobre este medicamento ou sintomas? Obtenha orientação de um médico qualificado, de forma prática e segura.